ClinicalTrials.gg
Not yet recruitingNCT07131969MAP-ALFUpdated Aug 26, 2025

Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis

An observational study in Acute Liver Failure and Sepsis, sponsored by University of Cambridge. Not yet recruiting at 7 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-26.

Sponsored by University of Cambridge · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Context Acute liver failure (ALF) is a life-threatening condition that occurs on the background of a healthy liver. The most common cause of acute liver failure in the UK is paracetamol overdose. Acute liver failure results from liver damage and activation of the body's inflammatory defences with subsequent damage to other organs including kidneys, lungs and heart. This often requires life support in an intensive care unit before liver transplantation (LT), the only currently available and effective rescue treatment for acute liver failure.

Challenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited.

Aim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant.

Importance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.

02

Conditions studied

  • Acute Liver Failure
  • Sepsis

Keywords

  • acute liver failure
  • sepsis
  • transcriptional analysis
  • predictors
  • paracetamol overdose
  • acetaminophen overdose
03

In context

Liver Failure, Acute

96 studies on the registry are indexed under Liver Failure, Acute; 20 are open to participants now.

This study's planned enrollment of 100 is below the median of 112 across 34 observational studies indexed under Liver Failure, Acute.

Browse Liver Failure, Acute studies →

Lead sponsor

University of Cambridge is the lead sponsor of 116 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute liver failure due to acetaminophen overdose OR sepsis who are admitted to ICU

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute liver failure due to acetaminophen (paracetamol) overdose admitted to ICU
  • all cause sepsis admitted to ICU

Exclusion criteria

Exclusion Criteria:

  • age \<16y
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with acute liver failure or sepsis

    Other: blood draw

Interventions

  • Otherblood draw

    Venous blood sampling into Tempus tube for RNA-sequencing

06

What researchers measure

Primary outcomes

  1. Mortality

    Time frame: From enrolment until at least 1-year

Secondary outcomes

  1. Transplant free survival

    30-day and 1-year survival without transplant

    Time frame: From enrolment to at least one year

  2. Length of stay - ICU and hospital

    Number of days stayed in ICU and in-hospital

    Time frame: From enrolment

  3. Transplant free mortality

    Death without transplant

    Time frame: From enrolment until death (at least until 1year)

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Aug 20, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07131969
Collaborators
European Society of Intensive Care Medicine
Responsible party
Dhupal Patel (Principal investigator, University of Cambridge) — Principal investigator
First posted
Aug 20, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion